Advertisement


Fabrice Denis, MD, PhD, on Lung Cancer: Improving OS With an App (French Language Version)

2016 ASCO Annual Meeting

Advertisement

Fabrice Denis, MD, PhD, of the Institut Inter-regional de Cancérologie Jean Bernard, discusses findings from a phase III trial on an app used between visits for early detection of symptomatic relapse and complications in high-risk lung cancer patients (Abstract LBA9006).

  To see the English language version of this discussion, click here.



Related Videos

Integrative Oncology
Palliative Care

Eric Roeland, MD, and Jennifer S. Temel, MD, on Integrative Palliative and Oncology Care

Eric Roeland, MD, of the University of California, San Diego, and Jennifer S. Temel, MD, of Massachusetts General Hospital, discuss findings that showed the benefits of offering palliative care integrated with oncology care (Abstracts 10003 and 10131).

Cost of Care
Issues in Oncology

Yousuf Zafar, MD, on the Financial Burden of Cancer Care

Yousuf Zafar, MD, of Duke Cancer Institute, summarizes his educational lecture on the financial toxicities of treatment and the need to focus on both short- and long-term interventions to reduce the burden on patients.

Multiple Myeloma

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial (Italian Language Version)

Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses in Italian results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000). 

 To see the English language version of this video, please click here.

Global Cancer Care

Nagi S. El-Saghir, MD, PhD, and Mary Gospodarowicz, MD, on The Middle Eastern Perspective of Cancer Research

Nagi S. El-Saghir, MD, of the American University of Beirut, and Mary Gospodarowicz, MD, of the Princess Margaret Hospital, discuss oncology from an international point of view.

Issues in Oncology

Maria Clemence Schwaederle, PharmD, on Precision Medicine: Its Impact in Refractory Malignancies

Maria Clemence Schwaederle, PharmD, of the University of California, San Diego, discusses an analysis of 13,203 patients in phase I clinical trials, which showed that a personalized strategy led to improved response rate and progression-free survival (Abstract 11520).

Advertisement

Advertisement




Advertisement